Biogen (BIIB) EBT Margin (2009 - 2026)
Biogen (BIIB) posted quarterly EBT Margin of 4.84% for Q2 2026, down 2328.0% year-over-year from 0.22% in Q2 2025, and down 68.25% quarter-over-quarter from 15.24% in Q1 2026.
Biogen (BIIB) EBT Margin (2009 - 2026) Analysis & Trends
Biogen's EBT Margin history runs 18 years deep, the most recent figure standing at 4.84% for Q2 2026.
- In Q2 2026, EBT Margin fell 2328.0% year-over-year to 4.84%; the TTM figure through Jun 2026 stood at 10.09% (down 790.0% YoY), while the FY2025 annual figure was 15.74%, down 396.0% from the prior year.
- EBT Margin for Q2 2026 stood at 4.84%, down from 15.24% in the prior quarter.
- The five-year high for EBT Margin was 54.66% in Q3 2022, with the low at 5.58% in Q3 2023.
- The 5-year median for EBT Margin is 18.04% (2023), against an average of 19.65%.
- The sharpest annual moves came in 2022 and 2023: EBT Margin soared 4418 bps in 2022, then sank 6024 bps in 2023.
- Biogen's EBT Margin stood at 23.73% in 2022, then tumbled by 49 bps to 12.22% in 2023, then slipped by 3 bps to 11.88% in 2024, then sank by 121 bps to 2.46% in 2025, then surged by 297 bps to 4.84% in 2026.
- Business Quant data shows BIIB's EBT Margin at 4.84% in Q2 2026, 15.24% in Q1 2026, and 2.46% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 29.63% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 18.19% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 27.53% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -131.41% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -4.34% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 4.21% |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 4.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.84% |
| Mar 31, 2026 | 15.24% |
| Dec 31, 2025 | -2.46% |
| Sep 30, 2025 | 21.99% |
| Jun 30, 2025 | 28.12% |
| Mar 31, 2025 | 12.80% |
| Dec 31, 2024 | 11.88% |
| Sep 30, 2024 | 18.29% |
| Jun 30, 2024 | 28.35% |
| Mar 31, 2024 | 20.29% |
| Dec 31, 2023 | 12.22% |
| Sep 30, 2023 | -5.58% |
| Jun 30, 2023 | 28.83% |
| Mar 31, 2023 | 17.80% |
| Dec 31, 2022 | 23.73% |
| Sep 30, 2022 | 54.66% |
| Jun 30, 2022 | 49.03% |
| Mar 31, 2022 | 13.72% |
| Dec 31, 2021 | 14.81% |
| Sep 30, 2021 | 10.48% |